{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:34:14Z","timestamp":1787758454304,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pancreatic duct adenocarcinoma is increasing in incidence without appreciable decrease in overall survival despite decades of heightened research. Its mortality rate approaches its incidence rate. We report a case of carcinoma of the pancreas that had complete response from adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>\n                      A 39-year old male radiographer presented with a 3-month history of progressively worsening epigastric pain radiating to the back, associated with history of weight loss, anorexia, and jaundice. Abdominal CT scan showed a mass in the head of pancreas. A Whipple's operation was planned for the patient. However, intraoperatively, the head and body of the pancreas were found to have been taken over by the tumor, which encased the portal vein as well. Multiple core needle biopsies of the pancreas were taken. Cholecystojejunostomy, gastrojejunostomy, and jejunojejunostomy were then done. Histopathologic analysis of the specimen revealed a well-differentiated adenocarcinoma of the pancreas. He was commenced on 28-day cycle of gemcitabine 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on Days 1, 8, and 15 plus capecitabine 830 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on Days 1\u201314. Repeat CT scan done after the 4\n                      <jats:sup>th<\/jats:sup>\n                      cycle showed no residual tumor in the pancreas. He has been in good health after 36 months follow-up, having received eight cycles of chemotherapy. He was counseled on resection of the pancreas, but he declined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Complete radiologic response may rarely occur after adjuvant chemotherapy for locally advanced adenocarcinoma of the pancreas. This does not, however, imply a cure of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_369_22","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:26:28Z","timestamp":1669166788000},"page":"1945-1948","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prolonged complete response after neoadjuvant capecitabine-gemcitabine for a locally advanced pancreatic adenocarcinoma"],"prefix":"10.4103","volume":"25","author":[{"given":"CN","family":"Ekwunife","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SE","family":"Enendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Okorie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lemchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IG","family":"Nnadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OC","family":"Iwuagwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20240907","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1200\/JOP.2015.009753","article-title":"Pancreatic adenocarcinoma: The emperor of all cancer maladies","volume":"12","author":"Tempero","year":"2016","journal-title":"J Oncol Pract"},{"key":"R2-25-20240907","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S160018","article-title":"Rising trends in pancreatic cancer incidence and mortality in 2000-2014","volume":"10","author":"Wu","year":"2018","journal-title":"Clin Epidemiol"},{"key":"R3-25-20240907","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R4-25-20240907","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4314\/thrb.v13i2.55226","article-title":"Cancer distribution pattern in south-western Nigeria","volume":"13","author":"Awodele","year":"2011","journal-title":"Tanzan J Health Res"},{"key":"R5-25-20240907","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R6-25-20240907","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X13478680","article-title":"Pancreatic cancer: Why is it so hard to treat?","volume":"6","author":"Oberstein","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"R7-25-20240907","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-25-20240907","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JOP.2016.017376","article-title":"Locally advanced unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline summary","volume":"13","author":"Balaban","year":"2017","journal-title":"J Oncol Pract"},{"key":"R9-25-20240907","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"R10-25-20240907","first-page":"340","article-title":"Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma","volume":"10","author":"Mathew","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"R11-25-20240907","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12885-016-2821-0","article-title":"Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer\u2014A case report and review","volume":"16","author":"Gostimir","year":"2016","journal-title":"BMC Cancer"},{"key":"R12-25-20240907","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15279\/kpba.2016.21.4.209","article-title":"Long term complete response of unresectable locally advanced pancreatic cancer after CCRT and Gemcitabine Chemotherapy","volume":"21","author":"Yang","year":"2016","journal-title":"Korean J Pancreas Biliary Tract"},{"key":"R13-25-20240907","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000497827","article-title":"Pathologic complete response of pancreatic cancer following neoadjuvant FOLFIRINOX treatment in hepatic metastasized pancreatic cancer","volume":"35","author":"Luu","year":"2019","journal-title":"Visc Med"},{"key":"R14-25-20240907","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3748\/wjg.v20.i24.7864","article-title":"Imaging diagnosis of pancreatic cancer: A state-of-the-art review","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R15-25-20240907","first-page":"1146","article-title":"Complete pathologic response to chemotherapy (FOLFORINOX) is not equivalent to cure: Case report and review of the literature","volume":"1","author":"Pozza","year":"2016","journal-title":"Clin Oncol"},{"key":"R16-25-20240907","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MPA.0000000000000392","article-title":"Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: A pancreatic cancer case-control consortium (PanC4) Analysis","volume":"45","author":"McWilliams","year":"2016","journal-title":"Pancreas"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_369_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:52Z","timestamp":1787757412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_369_22"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_369_22","relation":{},"ISSN":["1119-3077"],"issn-type":[{"value":"1119-3077","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}